Geron 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Geron reported 3rd quarter 2026 net product revenue of $60.1 million, compared with $47.2 million in Q3 of 2025, a 27% year-over-year increase.
- Rytelo demand grew 10% quarter over quarter, marking the 4th consecutive quarter of demand growth; prescribing accounts increased 8%, and the product had reached more than 1,700 accounts since launch.
- Gross-to-net deductions were 19.3% for the 3 months ended September 30th, 2026, compared with 21.6% for the same period in 2025.
- Research and development expenses were $12.7 million, compared with $21.1 million in the same period in 2025; selling, general, and administrative expenses were $35.7 million, compared with $39 million.
- Total operating expenses excluding COGS were $48.3 million, compared with $60.1 million in the same period in 2025, and operating expenses were down 9% year-to-date compared with the prior year.
- As of September 30th, 2026, Geron had approximately $339 million in cash, cash equivalents, restricted cash, and marketable securities, compared with $327 million as of June 30th, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to the Geron Corporation Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to Dawn Schottlandt, SVP Investor Relations and Corporate Affairs. You may begin. Good morning, everyone.
Welcome to the Geron Corporation Third Quarter 2026 Earnings Conference Call. Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those related to our 2026 financial guidance, our current RYTELO commercialization strategy, and related opportunities in the U.S. and the EU, the therapeutic potential of RYTELO, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources, and other statements that are not historical fact, which, of course, involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements.
Therefore, I refer you to the risks and uncertainties described in today's earnings release and other heading risk factors in Geron's most recent periodic report filed with the SEC, which identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements and future updates to Geron's risk and uncertainties disclosures, including in its upcoming quarterly report on Form 10-Q. Geron undertakes no duty or obligation to update its forward-looking statements. Joining me on today's call are several members of Geron's management team: Harout Semerjian, Chief Executive Officer, Ahmed ElNawawi, our Chief Commercial Officer, Dr. Joseph Eid, Executive Vice President, Research and Development, and Chief Medical Officer, and Michelle Robertson, our Chief Financial Officer. With that, I'll turn the call over to Harout to discuss Geron's progress in the third quarter.
Thank you, Dawn, and good morning, everyone. We continue to execute our strategy to build a leading hematology company. We're delivering consistent RYTELO demand growth, reinforcing our confidence in the lower-risk MDS U.S. commercial opportunity and RYTELO's growth trajectory over the next several years. We also initiated a gated commercial launch in targeted European markets that gives us the optionality to scale up RYTELO's availability through partnerships. Last week, we announced the discontinuation of the IMpactMF trial evaluating imetelstat in relapsed and refractory myelofibrosis following a recommendation by the independent DMC. We believe this is the right course of action for patients and for Geron. In the third quarter, we continued to see increased prescribing from community practices, leading to a quarter-over-quarter demand growth of 10% and net revenue growth of 5%, or $60.1 million. This represents a 27% increase in net revenue year-over-year.
This performance keeps us on track to achieve the mid to high end of our full year 2026 net revenue guidance range of $220 million-$240 million and reinforces our confidence that RYTELO has a long growth runway in the U.S. This year, we started executing our ex-U.S. go-to-market commercial strategy, focused on addressing unmet patient needs and broadening access to RYTELO while prioritizing U.S. price integrity. Recent developments, including the exclusion of orphan drugs like RYTELO from the CMS GLOBE model, gives us the opportunity to serve more patients globally. We initiated a gated commercial launch to make RYTELO available in targeted European markets, beginning with Germany, where RYTELO is expected to be commercially available by the end of this year.
In Europe, our approach enables us to retain strategic control of pricing without having to establish full infrastructure in each market or commit to a large upfront investment. This hybrid model also allows us to remain flexible and open to partnership opportunities. To support our global reach, we recently increased our engagement and presentations at multiple international medical meetings and were encouraged by the interest from hematologists in key markets. We will continue to explore opportunities in other geographies where we believe we can help address the significant unmet need of lower-risk MDS patients. As we continue to strengthen our operations, another area of focus for us is financial discipline, where our investments are intentional and targeted. Our operating expenses were down 9% year-to-date compared to the prior year, reflecting our continued focus on operational efficiency.
This discipline is enabling us to update our full year 2026 total operating expense guidance range from $220 million-$230 million. With $339 million of cash on hand, we have a strong balance sheet to fund our current operations, which gives us flexibility to pursue business development opportunities. With that, I'll turn it over to Nawawi to provide more detail on RYTELO's commercial performance and our execution.
Thank you, Harout. We are pleased to report our fourth consecutive quarter of demand growth for RYTELO, reinforcing the need for this drug and its potential long-term value as a preferred treatment in second-line lower-risk MDS. In the third quarter, we achieved a 10% demand growth for RYTELO compared to the second quarter of this year, an 8% increase in prescribing accounts, predominantly from community practices, expanding our footprint to more than 1,700 accounts since launch, with first and second-line patient starts on a rolling 12-month basis at 36%. We believe that RYTELO has the potential to deliver consistent quarter-over-quarter growth for years to come, driven in large part by continued adoption in the community setting, where there are still thousands of patients that can benefit from RYTELO.
Our focus is on accelerating that adoption through targeted personal and non-personal engagements that reinforce RYTELO's differentiated clinical efficacy in second-line lower-risk MDS patients, while continuously educating heme/oncs on dosing and management of cytopenias. RYTELO's unique mode of action as a first-in-class telomerase inhibitor, its broad label, and position in NCCN Guidelines provide a strong foundation to drive durable long-term growth. Turning to our efforts in Europe, we're taking a gated operational approach where we drive regulatory engagement and local reimbursement process to ensure RYTELO reaches the appropriate patients at a price that reflects its unique value. Our model allows us to broaden RYTELO's access with a staged upfront investment while preserving flexibility for the future. We have already initiated our launch in Europe and plan to make RYTELO commercially available in Germany by the end of the year, with France to follow in 2027.
We're encouraged by the interest we're seeing across markets, supported by investigator experience with imetelstat and the significant unmet need in lower-risk MDS. I now turn it over to Joe to discuss our medical and scientific engagement efforts.
Thanks, Nawawi. Last week, we announced our decision to discontinue the phase III IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed refractory myelofibrosis. This decision was based on the recommendation from the independent data monitoring committee, informing us that the trial was unlikely to meet its primary endpoint of overall survival. Importantly, there were no new safety signals observed in the trial that changed the known safety profile of imetelstat. We are committed to unblinding the data, conducting a detailed analysis of this rich dataset, and sharing findings at an upcoming medical meeting that may help inform future research. We are deeply grateful to the patients and families, as well as the investigators and clinical teams whose dedication made this research possible.
Turning to lower-risk MDS, this quarter we presented at leading hematology meetings, both global and regional, further communicating the growing body of evidence supporting RYTELO's differentiated profile, including evidence of disease-modifying activity. Just as importantly, these meetings created meaningful opportunities to engage directly with the medical community, exchange insights, and deepen scientific dialogue around the evolving treatment of lower-risk MDS. At SOHO, we continue to build strong momentum through impactful data presentations, sponsored education, and broad KOL engagement powered by a coordinated full-team approach. Our lower-risk MDS real-world evidence poster showed meaningful hemoglobin improvement with imetelstat despite short treatment duration and later-line use in U.S. community oncology practice in the immediate post-launch period. This marked the second real-world evidence presentation this year, adding to the growing body of evidence that reinforces findings from our phase III IMerge trial and the safety, efficacy, and tolerability profile of RYTELO.
Additional data presented at the 88th Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology further highlighted the durable clinical outcomes observed with imetelstat and expanded the growing body of evidence supporting its differentiated profile. Across the presentations, phase III IMerge findings and real-world experience reinforce the durability and clinical relevance of treatment outcomes, including findings suggesting that treatment-emergent cytopenias may reflect an on-target effect associated with meaningful clinical outcomes, such as hemoglobin improvement and transfusion independence in lower-risk MDS. Importantly, the presentations also demonstrated growing scientific interest and investigator experience with imetelstat outside the U.S. as we continue to deepen engagement with the global hematology community.
Beyond congress presentations, we continue to strengthen the scientific foundation of RYTELO through two manuscripts published in peer-reviewed journals, further expanding the body of evidence supporting imetelstat's role in lower-risk MDS and its potential to address significant unmet need. Looking ahead, the 68th ASH Annual Meeting in December will provide another opportunity to build on this body of evidence with new data across lower-risk MDS and other hematological diseases that will further inform our understanding of RYTELO's clinical potential. Our six accepted abstracts at ASH reinforce the clinical and biological evidence of RYTELO, and we look forward to sharing additional details later today. Our progress has been recognized beyond the medical community. We are honored to have been nominated for the Prix Galien USA Award for Best Product for Orphan or Rare Diseases.
This recognition represents decades of pioneering work in telomerase inhibition and, most importantly, a sustained commitment to addressing significant unmet needs for people living with lower-risk MDS. It is a meaningful acknowledgement of the science behind RYTELO and the potential to translate that science into better outcomes for patients. I'll now hand it over to Michelle to walk through the financials.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
